angiotensin-amide and Diabetes--Gestational

angiotensin-amide has been researched along with Diabetes--Gestational* in 1 studies

Other Studies

1 other study(ies) available for angiotensin-amide and Diabetes--Gestational

ArticleYear
Persistent elevation of fibroblast growth factor 23 concentrations in healthy appropriate-for-gestational-age preterm infants.
    Journal of pediatric endocrinology & metabolism : JPEM, 2015, Volume: 28, Issue:7-8

    To explore the temporal evolution of 25-hydroxyvitamin D [25(OH)D], its epimer, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and minerals in healthy appropriate-for-gestational-age preterms.. A prospective study was undertaken in infants born at 28-32 weeks with monitoring at 1, 3, 5 weeks and term.. Morning plasma and urine calcium; phosphorus; creatinine; PTH, C-terminal and intact FGF23 (iFGF23) and liquid chromatography-tandem mass spectrometry measurements of 25(OH)D were undertaken. Analyses included regression models.. Some 11 infants (5 males) were recruited at a median gestational age of 31.2 weeks (interquartile range: 28.1-31.8). Standard chemistries were normal. No infant was vitamin D deficient; 58% achieved 50 nmol/L with a median intake of 540 IU/day. High concentrations of C-3 epimer were detected. iFGF23 and C-terminal concentrations were persistently elevated (double and ten times adult norms, respectively). Tubular resorption of phosphorus was normal (88%±8%).. Most infants achieved acceptable 25(OH)D3 concentrations. The biologic significance of the elevated FGF23 is unclear.

    Topics: Adult; Angiotensin Amide; Biomarkers; Case-Control Studies; Chromatography, Liquid; Diabetes, Gestational; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Follow-Up Studies; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Male; Pre-Eclampsia; Pregnancy; Prognosis; Prospective Studies; Tandem Mass Spectrometry; Term Birth

2015